Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Blecua Carrillo Albornoz P, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N. Samstein RM, et al. Among authors: de stanchina e. Nat Cancer. 2021 Dec;1(12):1188-1203. doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16. Nat Cancer. 2021. PMID: 33834176 Free PMC article.
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.
Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E, Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-Bonnet G, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. Chang Q, et al. Among authors: de stanchina e. Neoplasia. 2013 Jul;15(7):848-62. doi: 10.1593/neo.13706. Neoplasia. 2013. PMID: 23814496 Free PMC article.
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
Gao SP, Chang Q, Mao N, Daly LA, Vogel R, Chan T, Liu SH, Bournazou E, Schori E, Zhang H, Brewer MR, Pao W, Morris L, Ladanyi M, Arcila M, Manova-Todorova K, de Stanchina E, Norton L, Levine RL, Altan-Bonnet G, Solit D, Zinda M, Huszar D, Lyden D, Bromberg JF. Gao SP, et al. Among authors: de stanchina e. Sci Signal. 2016 Mar 29;9(421):ra33. doi: 10.1126/scisignal.aac8460. Sci Signal. 2016. PMID: 27025877 Free PMC article.
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.
Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, D'Arcy P, Wang X, Kobos R, Antczak C, Bhinder B, Shum D, Radu C, Yang G, Taylor BS, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M. Shukla N, et al. Among authors: de stanchina e. Cancer Res. 2016 Aug 1;76(15):4525-34. doi: 10.1158/0008-5472.CAN-16-1040. Epub 2016 Jun 2. Cancer Res. 2016. PMID: 27256563 Free PMC article.
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.
Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM. Rodrik-Outmezguine VS, et al. Among authors: de stanchina e. Nature. 2016 Jun 9;534(7606):272-6. doi: 10.1038/nature17963. Epub 2016 May 18. Nature. 2016. PMID: 27279227 Free PMC article.
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM. Lok BH, et al. Among authors: de stanchina e. Clin Cancer Res. 2017 Jan 15;23(2):523-535. doi: 10.1158/1078-0432.CCR-16-1040. Epub 2016 Jul 20. Clin Cancer Res. 2017. PMID: 27440269 Free PMC article.
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. Toy W, et al. Among authors: de stanchina e. Cancer Discov. 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. Epub 2016 Dec 16. Cancer Discov. 2017. PMID: 27986707 Free PMC article.
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P. Xue Y, et al. Among authors: de stanchina e. Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17. Nat Med. 2017. PMID: 28714990 Free PMC article.
Pazopanib radio-sensitization of human sarcoma tumors.
Wang F, Li H, Markovsky E, Glass R, de Stanchina E, Powell SN, Schwartz GK, Haimovitz-Friedman A. Wang F, et al. Among authors: de stanchina e. Oncotarget. 2018 Jan 20;9(10):9311-9324. doi: 10.18632/oncotarget.24281. eCollection 2018 Feb 6. Oncotarget. 2018. PMID: 29507692 Free PMC article.
245 results